Did you know this version of Internet Explorer is out of date?

To get the latest experience from our website, please upgrade your browser.

Have a drug or medical device concern?

call

Bayer Group

A A

Bayer, a leading drug manufacturer, faces criticism and litigation over several of its products: Mirena IUD, Xarelto and Yaz birth control.

The Bayer Group is a leading global innovator in many areas, with 289 worldwide subsidiaries in health care, agriculture, synthetic materials and business solutions. Among them:

  • Bayer HealthCare is focused on pharmaceuticals, nonprescription medications and medical devices.
  • Bayer CropScience is focused on crop protection and pest control.
  • Bayer MaterialScience manufactures high-tech polymers, which are used in everything from the automotive and construction industries to footwear and textiles.
  • Bayer Business Technology and Services was established to support Bayer’s restructuring of North American subsidiaries in 2008 with services like business planning, consulting, HR, accounting, IT and infrastructure support.

Bayer Group employs more than 118,000 people worldwide with an established presence in North and South America, Europe, Asia, Africa, Australia and New Zealand. Its headquarters is located in Germany and nearly a third of its employees operate in Europe, making the continent its home market.

Fast Facts About Bayer
Established: 1863
Founders: Friedrich Bayer and Johann Friedrich Weskott
Headquarters: Leverkusen, Germany
Size: 118,900 employees worldwide
2014 Revenue: $25.4 billion

Bayer HealthCare is further broken down into four divisions: animal health, consumer care, medical care (diabetes management) and pharmaceuticals. The consumer-care division focuses on nonprescription medications and supplements and introduced the world to both aspirin and heroin. The consumer-care division is responsible for many well-known brands such as Midol, One A Day vitamins, Alka-Seltzer and Aleve.

In May 2014, Bayer agreed to buy Merck’s consumer care division for $14.2 billion. The acquisition gave it control of Claritin, Coppertone and Dr. Scholl’s products.

The pharmaceutical division consists of two parts: general medicine and specialty medicine (including diagnostic imaging). In the general-medicine sector, popular pharmaceuticals include the erectile dysfunction drug Levitra, cancer drug Nexavar, blood-clotting drug Kogenate and multiple-sclerosis drug Betaferon.

Bayer’s pharmaceutical division also focuses on women’s health, and has supported family planning since the introduction of “The Pill” more than 50 years ago. The company manufactures the popular birth-control pills Yaz and Yasmin, the birth control device Essure, as well as Mirena and Skyla, which are both intrauterine devices (IUDs).

Yaz and Yasmin are linked to an increased risk of potentially fatal blood clots. Essure can cause damage to the Fallopian tubes, and Mirena can cause uterine perforation and other serious side effects. Bayer faces lawsuits from women injured by its birth-control products. The company also faces claims that its new blood thinner, Xarelto, shows signs of creating side effects similar to Pradaxa, another blood thinner.

Free Case Review
Did one of Bayer’s products harm you?

Free Case Review

Please enter your contact information and the effect caused by the selected drug or device.

    History

    Dye salesman Friedrich Bayer and master dyer Johann Friedrich Weskott founded Bayer in 1863. Approaching the market of synthetic dyes with a research-and-development focus, they set the tone for the company’s future.

    Early success and expansion quickly took Bayer from a three-man shop to a 300-person workforce. In 1881, the company’s transition to a joint-stock corporation led to its development as an international chemical company, laid the financial foundation for expansion and established a pharmaceutical division.

    It built a scientific laboratory in Wuppertal-Elberfeld, Germany, near the company’s headquarters at the time. The company set new standards in research, such as the development of aspirin, which hit the market in 1899. In 1912, Leverkusen became the company’s headquarters. Bayer continued its international expansion, and by 1913 nearly 10 percent of its employees worked outside of Germany.

    World War I Halts Progress

    During World War I, Bayer began producing war materials like explosives and chemical weapons. However, as with many companies, the war halted progress for Bayer and devastated export markets. Inflation tapped out remaining financial reserves. Foreign assets, patents and trademarks, such as aspirin and heroin, were seized.

    From 1925 to 1951, Bayer incorporated into chemical conglomerate IG Farben and did not exist as an individual company. After the Allies dissolved IG Farben into 12 new companies, Bayer reemerged in 1951 as Farbenfabriken Bayer AG. Sites in Leverkusen, Elberfeld, Dormagen and Uerdingen were restored to the company, and Bayer received the subsidiary Agfa in 1952.

    From the 1950s to the 1970s, Bayer’s reconstruction helped the Federal Republic of Germany undergo the Wirtschaftswunder, which means “economic miracle.” While still under control of the Allies, the company was allowed to acquire foreign partnerships and resume international sales, with a focus on Latin America and the U.S.

    Acquisitions and Growth

    The company’s foundation in research and development again took hold, and the subsequent products and inventions contributed to further expansion. Bayer’s acquisition of Cutter Laboratories Inc. and Miles Laboratories, Inc. in the 1970s gave the company footing in the market of U.S. pharmaceuticals and led to increased sales for the region.

    The 1990s marked the increasing importance of development in North America. The milestone acquisition of Sterling Winthrop allowed Bayer to regain the rights to the “Bayer” company name and logo in the U.S. for the first time in 75 years. In 1995, its “pharmaceutical research triad” was completed, and its third facility was built in Japan.

    In the early 2000s, Bayer HealthCare, Bayer MaterialScience and Bayer CropScience were launched as legally independent subgroups. In 2006, Schering AG became Bayer’s largest acquisition, prompting a major expansion of the HealthCare division. Bayer acquired Conceptus Inc., the maker of Essure Birth Control, in 2013 for $1.1 billion. The company celebrated its 150th anniversary that year.

    Problematic Products

    Although Bayer is a trusted name, the company’s commitment to developing innovative health care solutions has not always been successful. The company introduced the world to an illicit narcotic and has seen a great deal of recent scrutiny over its birth control products Yaz, Yasmin and Mirena.

    Bayer developed and marketed the blood-thinner Xarelto in a partnership with Johnson & Johnson, but the drug faces hundreds of lawsuits by people who claimed they suffered uncontrollable bleeding events while taking the drug.

    Heroin

    Bayer marketed and distributed heroin as a non-addictive morphine and cough suppressant. Researcher and chemist Felix Hoffmann, who had just discovered modern-day aspirin two weeks prior, was experimenting to produce codeine, which is less potent and addictive than morphine. Instead, he produced heroin, which is twice as potent as morphine. Bayer marketed heroin as a cure for morphine addiction until it was discovered that it was actually a faster-acting form of morphine.

    In 1913, Bayer stopped producing heroin after seeing rising numbers of heroin-related hospitalizations and cases of drug abuse. In 1914, the U.S. passed a law to regulate its sale and distribution, but still allowed it to be manufactured, prescribed and sold for medical purposes. Following World War I, Bayer’s trademark rights to heroin and aspirin were seized under the Treaty of Versailles. In 1924, the U.S. Congress banned the sale, production and importation of heroin.

    Yaz/Yasmin

    Yaz, Yasmin and Ocella (the generic version) contain a different hormone, called drospirenone, than older birth-control pills. Studies backed by the FDA have warned that drospirenone can triple the risk of potentially fatal blood clots in patients, increasing chances of blood clots, deep vein thrombosis and pulmonary embolism as much as 74 percent.

    Yaz was put on the market in 2006. Since then, the company’s advertising practices concerning Yaz have been repeatedly disciplined by the FDA. The FDA has received thousands of complaints regarding the connection between Yaz and blood clots. In an update, the FDA reiterated its concern about the risks of blood clots with Yaz.

    More than 10,000 women filed lawsuits against Bayer and its affiliates over the adverse side effects of Yaz. It settled more than 8,000 cases for $1.7 billion.

    Mirena

    Mirena is a long-term, reversible form of birth control known as an IUD. Some women experienced life-threatening side effects after having it implanted. Side effects include perforation of the uterus, pelvic inflammatory disease, device expulsion, ectopic pregnancy and other pregnancy complications.

    One of the most dangerous side effects of Mirena is device migration. Migration refers to the IUD perforating the wall of the uterus and entering the abdominal cavity, pelvic organs or blood vessels, which causes pain, infection and organ damage.

    Lawsuits filed against Bayer claim the company failed to warn the public of the device’s susceptibility to spontaneously migrate and perforate the uterus, Bayer was aware of the dangerous risks and the company intentionally released a faulty product. Lawsuits also claim Bayer used advertising that oversold the IUD’s benefits and inadequately explained the risks.

    More than 360 cases against Bayer are pending in a multi-district litigation court in the U.S. District Court for the Southern District of New York.

    Essure

    Acquired as part of its buyout of Conceptus, Bayer began marketing Essure birth control in 2013. It was the only form of birth control that could be performed in an office without anesthesia at the time, and in some cases it took less than 10 minutes to implant. Studies also showed it was almost perfect at preventing pregnancy.

    Common side effects from Essure include cramping, vomiting and dizziness. A review of adverse events revealed thousands of cases of abdominal pain, heavy periods and headaches. Hundreds of women also reported feeling fatigue, experiencing weight fluctuations and possible nickel allergy reactions.

    Additionally, thousands of women reported injuries from Essure. According to reports, the device perforated fallopian tubes leading to severe pain, long-term injuries and infections. The most extreme complications included the deaths of five fetuses and four women.

    Those harmed filed Essure lawsuits and are fighting preemption laws that protect the device from litigation. Preemption laws protect manufacturers from lawsuits, because the devices were approved by the FDA. However, numerous lawsuits claim preemption laws shouldn’t apply, because Bayer allegedly manipulated clinical trial data.

    Xarelto

    Xarelto (rivaroxaban) is an oral medication developed by Bayer and marketed in the U.S. by Johnson & Johnson. It is a blood thinner used to prevent dangerous blood clots.

    With all anticoagulants, patients are more prone to excessive, uncontrolled bleeding. Hundreds of deaths have been attributed to the blood thinner Pradaxa, manufactured by Boehringer Ingelheim. Unlike older anticoagulants, Xarelto and Pradaxa have no known antidote to stop bleeding.

    Boehringer Ingelheim faced more than 4,000 Pradaxa lawsuits. The lawsuits blamed the company for concealing health risks, inadequately warning consumers of the severity of the drug’s bleeding side effects and failing to adequately test the drug before putting it on the market. The company settled more than 4,000 cases for $650 million in 2014.

    People suffering similar side effects while taking Bayer’s blood thinner filed lawsuits over Xarelto. Hundreds of those cases are pending in multi-district litigation courts in Philadelphia and Louisiana.

    Future of Bayer

    Bayer hopes new medicines like the vision-loss medication Eylea and cancer medication Stivarga will increase sales.

    In 2014, Bayer strengthened its oncology business with the acquisition of Algeta and its consumer-care business with the acquisition of Dihon Pharmaceutical Group in China. Bayer CropScience also acquired Land Management assets of DuPont Crop Protection later that year.

    Bayer plans to continue expansion and increase spending for research and development. The company also plans to develop on the enormous potential of the Asian/Pacific market.

    Free Case Review